Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.) |
|
| 2 | Active Comparator | Alprazolam Tablets, 2 mg, Xanax (The Upjohn Company) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.) | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Bioequivalence based on AUC and Cmax | 13 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Calvin F. Fuhrmann, M.D. | PharmaKinetics Laboratories Inc. | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D001008 | Anxiety Disorders |
| ID | Term |
|---|---|
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000525 | Alprazolam |
| ID | Term |
|---|---|
| D001569 | Benzodiazepines |
| D001552 | Benzazepines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D006571 | Heterocyclic Compounds |